Scholarlink

<p>Dynein cytoplasmic 2 heavy chain 1 (<i>DYNC2H1</i>) is reported to play a potential role in cancer immunotherapy. However, the association between <i>DYNC2H1</i> mutation and the clinical benefit of immunotherapy in non-small cell lung cancer (NSCLC) and melanoma remains to be elucidated. We collected data from three public immune checkpoint inhibitor (ICI)-treated NSCLC cohorts (<i>n</i> = 137 in total) and seven ICI-treated melanoma cohorts (<i>n</i> = 418 in total) to explore the potential of <i>DYNC2H1</i> mutation as a predictive biomarker. The clinical outcomes, including the objective response rate (ORR) and progression-free survival (PFS), of patients with <i>DYNC2H1</i> mutations are significantly better than those of patients with wild-type <i>DYNC2H1</i>. Multivariate Cox regression analysis confirmed that <i>DYNC2H1</i> mutation was an independent predictive factor for ICI efficacy in NSCLC and melanoma. In addition, <i>DYNC2H1</i> mutation exhibited no prognostic value for NSCLC or melanoma. Tumour mutational burden (TMB) and tumour neoantigen burden (TNB) were significantly higher in patients with <i>DYNC2H1</i> mutation than in those with wild-type <i>DYNC2H1</i> in both NSCLC and melanoma cohort. The analysis of immune-related genes and immune cell enrichment revealed an association between <i>DYNC2H1</i> mutation and increased immune infiltration, revealing a potential mechanism underlying the predictive role of <i>DYNC2H1</i> mutation in immunotherapy efficacy. In conclusion, <i>DYNC2H1</i> mutation serves as a predictive biomarker of ICI efficacy in NSCLC and melanoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma

  • 期刊论文

  • 发表日期：

    2025年2月12日

查看全文
  • Lu Yang,
  • Yanlong Feng,
  • Xuewen Liu,
  • Qin Zhang,
  • Yaqin Liu,
  • Xing Zhang,
  • Ping Li,
  • Dongsheng Chen

摘要

Dynein cytoplasmic 2 heavy chain 1 (DYNC2H1) is reported to play a potential role in cancer immunotherapy. However, the association between DYNC2H1 mutation and the clinical benefit of immunotherapy in non-small cell lung cancer (NSCLC) and melanoma remains to be elucidated. We collected data from three public immune checkpoint inhibitor (ICI)-treated NSCLC cohorts (n = 137 in total) and seven ICI-treated melanoma cohorts (n = 418 in total) to explore the potential of DYNC2H1 mutation as a predictive biomarker. The clinical outcomes, including the objective response rate (ORR) and progression-free survival (PFS), of patients with DYNC2H1 mutations are significantly better than those of patients with wild-type DYNC2H1. Multivariate Cox regression analysis confirmed that DYNC2H1 mutation was an independent predictive factor for ICI efficacy in NSCLC and melanoma. In addition, DYNC2H1 mutation exhibited no prognostic value for NSCLC or melanoma. Tumour mutational burden (TMB) and tumour neoantigen burden (TNB) were significantly higher in patients with DYNC2H1 mutation than in those with wild-type DYNC2H1 in both NSCLC and melanoma cohort. The analysis of immune-related genes and immune cell enrichment revealed an association between DYNC2H1 mutation and increased immune infiltration, revealing a potential mechanism underlying the predictive role of DYNC2H1 mutation in immunotherapy efficacy. In conclusion, DYNC2H1 mutation serves as a predictive biomarker of ICI efficacy in NSCLC and melanoma.